Identification of Bacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosamine polysaccharide.

Journal of Clinical Microbiology
J W EzzellC Brown

Abstract

Guanidine extracts of crude Bacillus anthracis cell wall were used to vaccinate BALB/c mice and to develop monoclonal antibody (MAb) to vegetative cell surface antigens. Two hybridomas selected during this study produced immunoglobulin M immunoglobulins, which appear to be directed to an epitope associated with the galactose-N-acetyl-D-glucosamine polysaccharide. Both demonstrated specificity in their binding to purified B. anthracis cell wall, o-stearoyl-polysaccharide conjugates, and intact, nonencapsulated vegetative cells. The interaction of the MAbs with purified polysaccharide was inhibited by 0.5 M galactose and lactose but not by N-acetylglucosamine, glutamate, glycine, or glycerol. Inhibition by glucose or sucrose was approximately 75% of that seen with galactose. Electron microscopy showed that both MAbs interacted with the cell wall of vegetative cells as well as with the cortex of spores. Neither MAb reacted with encapsulated vegetative cells, such as those from infected guinea pigs, nor did they react with intact spores. After conjugation to fluorescein isothiocyanate, the MAbs stained intensely all B. anthracis strains tested, whereas with two exceptions, none of the strains of 20 other Bacillus spp. was stained. ...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
May 1, 1986·Infection and Immunity·B E IvinsS H Leppla
Feb 1, 1988·Infection and Immunity·J W Ezzell, T G Abshire
Aug 1, 1985·Infection and Immunity·B D GreenB E Ivins
Aug 1, 1985·Journal of Medical Microbiology·N A LoganR C Berkeley
Dec 1, 1972·Bacteriological Reviews·K H Schleifer, O Kandler
Jan 1, 1983·Infection and Immunity·P MikesellT M Dreier
Jan 1, 1983·Infection and Immunity·J D Ristroph, B E Ivins
Jan 1, 1984·Journal of Clinical Microbiology·H B ColeR J Doyle
Jun 1, 1984·European Journal of Clinical Microbiology·K GrahamR Doyle
May 1, 1959·Journal of Bacteriology·J M LEISES W FREED

❮ Previous
Next ❯

Citations

Feb 7, 2001·Applied and Environmental Microbiology·S G BavykinA D Mirzabekov
Jul 15, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rachel SchneersonJohn B Robbins
Nov 12, 2005·Analytical and Bioanalytical Chemistry·Katie A EdwardsAntje J Baeumner
Jun 21, 2006·Applied Immunohistochemistry & Molecular Morphology : AIMM·Kathleen M TattiSherif R Zaki
Mar 17, 2007·Critical Reviews in Biotechnology·Joerg M Buescher, Argyrios Margaritis
Sep 20, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Mark W LisanbyJohn F Kearney
Oct 11, 2012·Bacteriophage·David A SchofieldCaroline Westwater
Jul 1, 1994·Veterinary Pathology·E D McGeeN K Jaax
Nov 1, 1996·Australian Veterinary Journal·D ForshawI J Links
Aug 16, 2005·FEMS Microbiology Letters·Iain AndersonNatalia Ivanova
May 12, 2007·Molecular Microbiology·Christopher T SteichenCharles L Turnbough
May 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Melissa K SwieckiJohn F Kearney
Jun 1, 2003·Nutrition Research Reviews·Jerry M Wells, Marjon H J Bennik
May 5, 2006·Applied and Environmental Microbiology·Elke Saile, Theresa M Koehler
Jan 1, 1992·The Journal of Applied Bacteriology·P C TurnbullJ Melling
Dec 2, 2020·Microorganisms·Alice ChateauAntonella Fioravanti
Jun 18, 2017·Annual Review of Microbiology·Dominique Missiakas, Olaf Schneewind
Sep 8, 2005·Journal of Clinical Microbiology·T G AbshireJ W Ezzell
Jun 5, 2003·Journal of Microbiological Methods·Alvin FoxRobert L Price
Jul 4, 2006·Clinics in Laboratory Medicine·Aileen M Marty
May 7, 2016·ACS Infectious Diseases·Katie J MolohonDouglas A Mitchell
Jul 18, 2009·Molecular Aspects of Medicine·Agnès Fouet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.